ATROPINE (AUTOINJECTOR)
Peakatropine injection, 2 mg
NDAINTRAMUSCULARSOLUTIONPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ATROPINE (AUTOINJECTOR) (atropine injection, 2 mg) is cholinergic antagonists [moa]. Approved for poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity, carbamate insecticides in adults. First approved in 2018.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Atropine autoinjector 2 mg is an intramuscular anticholinergic solution approved in 2018 for emergency treatment of poisoning by organophosphorus nerve agents and carbamate insecticides. It works as a cholinergic antagonist by blocking acetylcholine receptors to counteract excessive cholinergic stimulation. This is a critical life-saving product for acute toxicological emergencies.
Peak
Peak-stage lifecycle indicates mature market positioning with established distribution; modest competitive pressure (30) suggests stable team structure.
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.